PE20060359A1 - ESTRADIOL PRODROGS - Google Patents

ESTRADIOL PRODROGS

Info

Publication number
PE20060359A1
PE20060359A1 PE2005000557A PE2005000557A PE20060359A1 PE 20060359 A1 PE20060359 A1 PE 20060359A1 PE 2005000557 A PE2005000557 A PE 2005000557A PE 2005000557 A PE2005000557 A PE 2005000557A PE 20060359 A1 PE20060359 A1 PE 20060359A1
Authority
PE
Peru
Prior art keywords
ilo
trien
prodrogs
estradiol
sulfamoylbenzoate
Prior art date
Application number
PE2005000557A
Other languages
Spanish (es)
Inventor
Peter Droescher
Walter Elger
Alexander Hillisch
Gudrun Reddersen
Ralf Wyrwa
Sven Ring
Birgitt Schneider
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34969196&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060359(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20060359A1 publication Critical patent/PE20060359A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE n ES 0 A 4; R1 ES SO2NH2 O NHSO2NH2, DONDE R2, R3, X Y X1 SON H, HALOGENO, NITRILO, ENTRE OTROS; n ES 0, 1, 2, 3 O 4. SON COMPUESTOS PREFERIDOS: 3'-SULFAMOILBENZOATO DE 3-ACETOXIESTRA-1,3,5(10)-TRIEN-17b-ILO, 3'-SULFAMOILBENZOATO DE 3-TER-BUTILDIMETIL-SILILOXIESTRA-1,3,5/10)-TRIEN-17b-ILO, 2'-CLORO-5'-SULFAMOILBENZOATO DE 3-HIDROXIESTRA-1,3,5(10)-TRIEN-17b-ILO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION Y AUN PROCEDIMIENTO. DICHOS COMPUESTOS TIENEN ACTIVIDAD ESTROGENAREFERRING TO A COMPOUND OF FORMULA I, WHERE n IS 0 TO 4; R1 IS SO2NH2 OR NHSO2NH2, WHERE R2, R3, X AND X1 ARE H, HALOGEN, NITRILE, AMONG OTHERS; n IS 0, 1, 2, 3 OR 4. THE PREFERRED COMPOUNDS ARE: 3'-ACETOXYSTRA-1,3,5 (10) -TRIEN-17b-ILO, 3'-SULFAMOYLBENZOATE 3-TER-BUTYLBENZOATE -SILILOXYESTRA-1,3,5 / 10) -TRIEN-17b-ILO, 3-HYDROXYSTRA-1,3,5 (10) -TRIEN-17b-ILO 2'-CHLORO-5'-SULFAMOYLBENZOATE, AMONG OTHERS. IT IS ALSO REFERRED TO A COMPOSITION AND EVEN PROCEDURE. SAID COMPOUNDS HAVE ESTROGENIC ACTIVITY

PE2005000557A 2004-05-21 2005-05-20 ESTRADIOL PRODROGS PE20060359A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004025966A DE102004025966A1 (en) 2004-05-21 2004-05-21 Estradiol prodrugs

Publications (1)

Publication Number Publication Date
PE20060359A1 true PE20060359A1 (en) 2006-05-25

Family

ID=34969196

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000557A PE20060359A1 (en) 2004-05-21 2005-05-20 ESTRADIOL PRODROGS

Country Status (11)

Country Link
EP (1) EP1747230A1 (en)
JP (1) JP2007538025A (en)
AR (1) AR050335A1 (en)
DE (1) DE102004025966A1 (en)
GT (1) GT200500121A (en)
PA (1) PA8633701A1 (en)
PE (1) PE20060359A1 (en)
SV (1) SV2006002121A (en)
TW (1) TW200613315A (en)
UY (1) UY28909A1 (en)
WO (1) WO2005113574A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (en) 2000-05-31 2001-12-13 Jenapharm Gmbh Compounds with a sulfonamide group and pharmaceutical compositions containing these compounds
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102004025985A1 (en) * 2004-05-21 2005-12-15 Schering Ag Estriol and estetrol prodrugs
DE102005057224A1 (en) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag New 9-alpha substituted estratriene derivatives esterified with a sulfamoylphenyl-substituted acid residue, are prodrugs useful as carboanhydrase inhibitors for treating estrogen deficiency disorders
DE102005057225A1 (en) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag New 8-beta-substituted estratriene derivatives esterified with a sulfamoylphenyl-substituted acid residue, are prodrugs useful as carboanhydrase inhibitors for treating estrogen deficiency disorders
DE102005057408A1 (en) * 2005-11-30 2007-05-31 Bayer Schering Pharma Ag New sulfamoylsulfonate prodrugs e.g. useful for protecting red blood cells from attack by parasites or for hormone replacement therapy, female fertility control or treating hormone-associated diseases
US9745338B2 (en) * 2013-07-11 2017-08-29 Evestra, Inc. Pro-drug forming compounds
CN115368427B (en) * 2022-08-17 2024-02-13 南宁师范大学 Estradiol selenocyanate compound and preparation method and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1238739A (en) * 1958-08-04 1960-08-19 Chimiotherapie Lab Franc Process for the preparation of water-soluble testosterone derivatives
FR8290M (en) * 1968-12-31 1970-11-09 Rech Chimiques Et Ind Mar Lab
US5001234A (en) * 1987-04-16 1991-03-19 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5571933A (en) * 1994-11-17 1996-11-05 Duquesne University Of The Holy Ghost Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use
DE19712488A1 (en) * 1997-03-25 1998-10-01 Knoell Hans Forschung Ev Steroid sulfamates, processes for their preparation and use thereof
EP1284272A4 (en) * 2000-04-24 2003-09-10 Kyowa Hakko Kogyo Kk Estra-1,3,5(10)-triene derivatives
DE10027887A1 (en) * 2000-05-31 2001-12-13 Jenapharm Gmbh Compounds with a sulfonamide group and pharmaceutical compositions containing these compounds
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
GB0316290D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
TWI331154B (en) * 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
DE102004025985A1 (en) * 2004-05-21 2005-12-15 Schering Ag Estriol and estetrol prodrugs

Also Published As

Publication number Publication date
TW200613315A (en) 2006-05-01
EP1747230A1 (en) 2007-01-31
UY28909A1 (en) 2005-12-30
WO2005113574A1 (en) 2005-12-01
SV2006002121A (en) 2006-02-15
DE102004025966A1 (en) 2005-12-15
JP2007538025A (en) 2007-12-27
PA8633701A1 (en) 2006-07-03
GT200500121A (en) 2006-01-30
AR050335A1 (en) 2006-10-18

Similar Documents

Publication Publication Date Title
PE20060359A1 (en) ESTRADIOL PRODROGS
LUC00153I2 (en)
NO20035327D0 (en) Biologically active methylene-blue derivatives
NO20052787D0 (en) N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobial agents
MXPA06012595A (en) Amino-tetrazoles analogues and methods of use.
ATE487493T1 (en) AZOLIC ACID DERIVATIVES, ALONE OR IN COMBINATION, FOR THE TREATMENT OF DIABETES AND DYSLIPIDAEMIA; AND FOR THE TREATMENT OF MALIGNANT DISEASES
BR0317715A (en) Compositions and processes of use of collajolie
IN2012DN02609A (en)
UA93351C2 (en) Phthalazine derivatives as parp inhibitors
MXPA03007140A (en) Chemical compounds.
HK1088890A1 (en) Biguanide and dihydrotriazine derivatives
DE60334536D1 (en) FURYLVERBINDUNGEN
MXPA04004347A (en) Novel difunctional photoinitiators.
ATE403429T1 (en) SPIROPYRAZOLE COMPOUNDS
DK1791428T3 (en) Composition for the treatment of seed
NO20052788L (en) N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobial agents
ECSP077130A (en) USE OF 2-TIO-3,5-DICIANO-4-FENIL-6-AMINOPIRIDINES REPLACED IN THE TREATMENT OF NAUSE AND VOMITS
HK1087040A1 (en) Compounds for the treatment of metabolic disorders
SE0004245D0 (en) Novel compounds and their use
MXPA03002911A (en) Chemical compounds.
ATE300543T1 (en) CONDENSED PYRAZINEDIONE DERIVATIVES AS PDE5 INHIBITERS
DK1531672T3 (en) Antimicrobial Compositions
EA200401095A1 (en) OXA-AND TIADIAZOLES AND THEIR APPLICATION AS METALLOPROTEINAS INHIBITORS AS
EA200800681A1 (en) KIRALAXYL APPLICATION FOR PROTECTION AGAINST PHYTOPATHOGENES AND RELATED METHODS AND COMPOSITIONS
DE60112960D1 (en) CONDENSED PYRIDOINDOL DERIVATIVES

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed